Patents by Inventor Michele Pollock

Michele Pollock has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9254288
    Abstract: This disclosure provides tyrosine kinase protein and nucleic acid variants, particularly FGFR2 variants, which are linked to drug resistance. The disclosure further provides methods of diagnosis and theranosis, using these molecules and fragments thereof, and kits for employing these methods and compositions.
    Type: Grant
    Filed: May 7, 2013
    Date of Patent: February 9, 2016
    Assignees: THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE, QUEENSLAND UNIVERSITY OF TECHNOLOGY
    Inventor: Pamela Michelle Pollock
  • Patent number: 9140689
    Abstract: This disclosure provides tyrosine kinase protein and nucleic acid variants, particularly FGFR2 variants, which are linked to drug resistance. The disclosure further provides methods of diagnosis and theranosis, and development of new therapeutic agents using these molecules and fragments thereof, and kits for employing these methods and compositions.
    Type: Grant
    Filed: March 14, 2011
    Date of Patent: September 22, 2015
    Assignees: Translational Genomics Research Institute, Queensland University of Technology
    Inventors: Sara Ann Byron, Pamela Michelle Pollock
  • Publication number: 20130296326
    Abstract: This disclosure provides tyrosine kinase protein and nucleic acid variants, particularly FGFR2 variants, which are linked to drug resistance. The disclosure further provides methods of diagnosis and theranosis, using these molecules and fragments thereof, and kits for employing these methods and compositions.
    Type: Application
    Filed: May 7, 2013
    Publication date: November 7, 2013
    Applicant: TRANSLATIONAL GENOMICS RESEARCH INSTITUTE
    Inventor: Pamela Michelle Pollock
  • Publication number: 20110275084
    Abstract: This disclosure provides tyrosine kinase protein and nucleic acid variants, particularly FGFR2 variants, which are linked to drug resistance. The disclosure further provides methods of diagnosis and theranosis, and development of new therapeutic agents using these molecules and fragments thereof, and kits for employing these methods and compositions.
    Type: Application
    Filed: March 14, 2011
    Publication date: November 10, 2011
    Applicant: The Translational Genomics Research Institute
    Inventors: Sara Ann Byron, Pamela Michelle Pollock
  • Publication number: 20060287874
    Abstract: Described are a computer-implemented system and methods for the aggregation, organization and management of material related to the selection and pursuit of targeted applications for the sale of products. A system receives application inputs of three types: account selection aspects, video production aspects and application profile aspects. A user interface receives application inputs related to a particular sales opportunity and links related application inputs to one another. A rules engine authorizes generation of the outputs for evaluation and pursuit of a given sales opportunity when the user interface has received an account selection aspect, a video production aspect and an application profile aspect for that sales opportunities. The methods are directed to management of the account selection aspects, video production aspects and application profile aspects.
    Type: Application
    Filed: June 17, 2005
    Publication date: December 21, 2006
    Inventors: Eric Askeland, Michele Pollock, Scott Buss
  • Publication number: 20060141881
    Abstract: A wipe is provided that includes a first wiping member bonded to a backing member along valleys, whereby the wiping member includes a plurality of discrete peaks, and an adhesive is provided, in one embodiment, in the valleys and not on the peaks.
    Type: Application
    Filed: February 24, 2006
    Publication date: June 29, 2006
    Inventors: Ronald Bergsten, John Erickson, Daneeta Erickson, Thomas Haskett, Michele Pollock, Yasuo Sudo
  • Patent number: 6872536
    Abstract: Radiopharmaceuticals comprising molecules that target to N-formyl-methionyl-leucy-phenylalanine (fMLF) receptor on leukocytes in order to target sites of inflammation for diagnostic imaging are described. The targeting molecules are attached to capping groups that make the entire molecule either antagonists or weak agonists of fMLF receptor and therefore do not elicit a chemotactic response resulting in neutropenia. The preferred targeting molecule is ReO-Gly-lys(Dimethylgly-t-Butylgly-cys-gly)glu-trp-phe-leu-nle-NHCOcyclopropyl (wherein the peptide sequence NLeu-Leu-Phe-Trp-Glu-Lys-Gly is SEQ. ID No. 1.) The invention also relates to the use of combinatorial chemistry to obtain preferred molecules that target sites of inflammation for diagnostic imaging.
    Type: Grant
    Filed: November 10, 1999
    Date of Patent: March 29, 2005
    Assignee: Bracco Imaging S.p.A.
    Inventors: David Roe, Christine Maria Ribic, Betty Chee-Ion Lawrence, Catherine Michelle Pollock, Alfred Pollack